Pediatric Exclusivity Determinations Made under Section 505A of the Federal Food, Drug, and Cosmetic Act (the Act), as amended by the FDA Amendments Act of 2007 (FDAAA)

In accordance with section 505A(e)(1) of the Act, as amended by FDAAA (Pub. L. No. 110-85), the following list identifies those approved drugs for which a pediatric exclusivity determination was made, on or after September 27, 2007.  In addition, it provides a link to a copy of the Written Request and any amendments.

NOTE: Only applications held by the identified sponsor were granted pediatric exclusivity. We will update this page each time a determination is made.

The administrative amendments issued during the summer of 2002 and spring of 2004, which cover the passage of the Best Pharmaceuticals for Children Act on January 4, 2002, and the requirement for submitted reports to include more specific information on racial and ethnic minorities, respectively, may not be listed below for original Written Requests that predate their release (e.g., bicalutamide).

N=69

 

Drug

Sponsor

Determination Date

Written Request and Related Documents

Albuterol

GlaxoSmithKline

8/27/2008

Alfuzosin

Sanofi Aventis

9/7/2010

Almotriptan

Johnson & Johnson Pharmaceutical Research & Development

1/13/2009

Anastrozole

AstraZeneca

11/14/2007

Aripiprazole

Otsuka

11/14/2007

Asenapine New!

Forest Labs

3/3/2015

Bendamustine

Cephalon

5/24/2012

Bicalutamide

AstraZeneca

9/19/2008

Bivalirudin

The Medicines Company

6/17/2009

Candesartan

AstraZeneca Pharmaceuticals LP

7/20/2009

Capecitabine

Hoffman-La Roche, Inc.

8/28/2013

 

Caspofungin

Merck & Co., Inc.

4/15/2008

Clopidogrel

Sanofi Aventis

1/20/2011

Colesevelam

Daiichi Sankyo Pharma

2/17/2009

Darunavir

Tibotec

6/7/2011

Dexmedetomidine

Hospira

3/12/2013

Difluprednate

Alcon

3/21/2013

Docetaxel

Sanofi Aventis

3/17/2010

Duloxetine

Eli Lilly

7/2/2012

Efavirenz

BMS

1/29/2013

Entecavir

BMS

12/5/2013

Eplerenone

Pfizer

10/24/2007

Erlotinib New!

OSI Pharmaceuticals

3/18/2015

Esomeprazole

AstraZeneca LP

5/1/2009

Eszopiclone

Sunovion

6/29/2012

Everolimus

Novartis

7/10/2012

Ezetimibe

Schering Corporation

2/14/2008

Famciclovir

Novartis

9/21/2009

Finafloxacin

Alcon

8/25/2014

Fosamprenavir

ViiV Healthcare

1/10/2012

Fulvestrant

AstraZeneca

2/1/2011

Gatifloxacin

Allergan

5/19/2009

Guanfacine

Shire

10/17/2014

Ixabepilone 

BMS

4/5/2011

Lansoprazole

Tap Pharmaceutical Products, Inc.

7/15/2008

Levetiracetam

UCB, Inc.

6/3/2008

Levocetirizine

UCB, Inc.

8/25/2009

Loteprednol/Tobramycin

Bausch & Lomb

12/28/2010

Lopinavir/Ritonavir

Abbott Laboratories

3/7/2008

Memantine

Forest Labs

6/16/2014

Nitric Oxide

INO Therapeutics

11/2/2010

Olmesartan

Daiichi Sankyo

10/7/2009

Olopatadine

Alcon Research, Ltd.

8/12/2009

Olopatadine

Alcon Research, Ltd.

12/16/2014

Paliperidone

Ortho-McNeil-Janssen Pharmaceuticals, Inc.

1/5/2011

Palonosetron 

Helsinn

4/10/2014

 

Pantoprazole

Wyeth Pharmaceuticals, Inc.

2/17/2009

Pemetrexed

Eli Lilly

12/3/2010

Quetiapine

AstraZeneca Pharmaceuticals LP

1/23/2009

Rabeprazole

Eisai

12/4/2012

Risedronate

Procter & Gamble Pharmaceuticals, Inc.

4/24/2009

Rizatriptan

Merck

9/20/2011

Rocuronium

Organon, Inc.

4/3/2008

Rosuvastatin

AstraZeneca Pharmaceuticals LP

7/7/2009

Rufinamide

Eisai

1/13/2015

Sapropterin

BioMarin

3/13/2014

Saquinavir

Hoffman-La Roche, Inc.

10/26/2010

Sildenafil

Pfizer

2/9/2012

Tamsulosin

Boehringer Ingelheim

9/17/2009

Technetium Tc99 sestamibi

BMS

1/11/2008

Temsirolimus

Pfizer

2/28/2012

Tenofovir

Gilead Sciences, Inc.

9/6/2011

Tipranavir

Boehringer Ingelheim Pharmaceuticals, Inc.

3/7/2008

Topiramate

Ortho-McNeil-Janssen Pharmaceuticals, Inc.

7/24/2008

Valacyclovir

GlaxoSmithKline

2/28/2008

Valganciclovir

Hoffman-La Roche Inc.

7/24/2008

Valproate

Abbott

12/14/2007

Vigabatrin

Lundbeck

10/3/2013

Zoledronic acid

Novartis

12/21/2007

* Persons with disabilities having problems accessing the PDF files may call (301) 796-3634 for assistance.

 

 

Posted on the FDA website on 20 March 2015